The FDA is further elevating a pacemaker recall from Boston Scientific that it first broadcast in December over certain Accolade implants that can place themselves into a permanent safety | In addition to the previously disclosed two deaths,

In a wide manufacturing room with white walls and low ceilings, Boston Scientific employees combine components into finished consoles holding the brains of its medical devices, with automated tests collecting thousands of data points for quality control.

Medical device giant Boston Scientific has announced that it has signed a definitive agreement to acquire Israeli medical device company SoniVie for an immediate payment of $360 million as well as milestone payments of up to $180 million.

Boston Scientific has led a $175 million funding round for the mitral valve developer 4C Medical, which is currently working on an international pivotal study. | Boston Scientific led a $175 million funding round for 4C Medical,

Boston Scientific (NYSE: BSX) announced today that it agreed to acquire intravascular ultrasound system developer SoniVie.

Faraflex offers "more precision and higher fidelity mapping capability to understand the heart tissue," Boston Scientific's Dr. Brad Sutton said.

Migliaccio & Rathod is investigating a recent recall of the Accolade Pacemaker produced by Boston Scientific. If you have one of these pacemakers we would like to speak with you. Please complete the contact form on this page,

Boston Scientific has recalled its Accolade pacemaker devices due to a manufacturing issue that could cause the devices to enter safety mode, requiring replacement.

C Medical Technologies announced today that it closed a Series D financing round resulting in gross proceeds of up to $175 million.

Boston Scientific Corporation announced it has entered into a definitive agreement to acquire SoniVie Ltd., a privately held medic

TUESDAY, Feb. 25, 2025 (HealthDay News) -- Boston Scientific has issued a recall ... the device to permanently enter Safety Mode. The FDA is working with the manufacturer to assess the risk ...

He repeatedly assured Republican and Democratic senators he would follow the “scientific process” at FDA. But he wouldn’t commit to specific actions on a host of hot-button issues ...